Uso ético da biodiversidade brasileira: necessidade e oportunidade

Nowadays, Brazil and other developing countries are simple pharmaceutical technologies buyers or are only paying royalties to foreign laboratories. These facts make the public health system raise very expensive or can't put up attend to the specific necessities of these countries. The renewed global interest for natural products, such as phytotherapics, phytomedicines, cosmetics and nutraceuticals, has been stimulating industrialized countries investment in bioprospection. These evidences should stimulate the arguments, specially in developing countries, rich in natural resources and traditional knowledge, like Brazil, on the necessity of national health politics, based on their need and capacity, and on the economical opportunities that the ethical use of the biodiversity presents.